Spyre Therapeutics, Inc.
- SYRE
- NASDAQ
- Biotechnology
- Inflammatory Bowel Disease (IBD)
- Monoclonal Antibody Therapies
$79.90
Today −0.25%Quote Oct 16, 2026, 08:00 PM UTC
−13.79%over the last month
Max drawdown −15.6%From 1-month high −14.3%3 months −17.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$7.37B
Quote Oct 16
Next earnings
Nov 3
Expected, not confirmed
Analyst target
$119.89
+50.1% from here
Floor
$76.82
3.9% below price
Where the price sits
13 analysts
Analyst range, low to high
$107.00$130.00
- Price $79.90
- Resistance $85.92
- Consensus $119.89
Analysts' average target sits about 50% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about SYREPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
125
Founded
2013